View Clinical Trial (Medical Research Study)
Effect on Anxiety in Partial Epilepsy Patients Treated With Pregabalin - NCT01128712-07601(Clinical Trial 650939)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Hackensack |
|
State:
|
|
NJ |
| Zip Code: |
|
07601 |
| Conditions: |
|
Refractory Partial Epilepsy |
| Purpose: |
|
To prospectively demonstrate the superior anxiolytic effect of high dose pregabalin (PGB)
therapy (450 mg/day) compared to low dose PGB therapy (150 mg/day) in subjects with
medically refractory partial epilepsy not fully controlled despite treatment with 1-2
concomitant antiepileptic drugs (AEDs).
|
| Study summary: |
|
Background
Interictal anxiety symptoms are reported in two-thirds of patients with epilepsy and
represent an underrecognized and undertreated aspect of the disorder. Interictal anxiety is
postulated to stem from both fear of seizure recurrence ("seizure phobia") and dispersed
locus of control.In addition, anxiety and the most common forms of partial onset epilepsy
are viewed to arise from dysfunction in a common neurobiological substrate-the amygdala and
other structures within the limbic system.
Background on Pregabalin
Pregabalin (CI-1008,Lyrica) is a chemical analogue of the mammalian neurotransmitter
gamma-aminobutyric acid (GABA),although it does not bind to or activates GABA receptors or
inhibit GABA uptake. Pregabalin is an alpha-2-delta ligand that has analgesic, anxiolytic,
and antiepileptic activity.
Rationale
Antiepileptic drugs (AEDs) are commonly used for mood disorders including anxiety.Pregabalin
(PGB) the most recently FDA-approved AED for add-on therapy for refractory partial seizures
also has demonstrated efficacy in Generalized Anxiety Disorder. PGB binds to the
alpha-2-delta subunit protein of voltage-gated calcium channels, and in animal models, has
anxiolytic and anti-epileptic effects via pre-synaptic inhibition of the release of several
excitatory neurotransmitters. |
| Criteria: |
|
Inclusion Criteria:
1. An IRB-approved consent form signed and dated by the subject or legal representative.
2. A diagnosis of partial epilepsy of at least 2 years duration and failed treatment
with at least 2 AEDs.
3. Subjects from 18 to 75 years, both inclusive.
4. Females without childbearing potential (pre-menarcheal, post-menopausal, bilateral
oophorectomy or tubal ligation, complete hysterectomy, or medically accepted form of
contraception).
5. Subject judged by the Investigator to be reliable and capable of adhering to the
protocol, visit schedules, and able to understand and complete study instruments.
6. CT or MRI scan performed within 2 years of screening and without evidence of a
progressive lesion or neurological condition.
7. Electroencephalogram consistent with partial epilepsy and does not demonstrate
generalized spike wave.
8. Currently treated with a stable dose of 1-2 AEDs for a minimum of 4 weeks (3 months
for phenobarbital and primidone). Benzodiazepines used as a rescue therapy for
seizures and used no more than once a week will be permitted.
Exclusion Criteria:
1. History of psychogenic non-epileptic seizures.
2. The subject is pregnant or lactating.
3. Women with reproductive potential who refuse to use medically accepted forms of birth
control.
4. Presence of any clinically significant laboratory abnormality which in the judgement
of the investigator should exclude the subject from the study.
5. Presence of any progressive,demyelinating, or degenerative neurological condition.
6. Subject is currently taking gabapentin.
7. History of an allergic reaction to gabapentin or PGB.
8. History of worsened seizures or serious adverse reactions to gabapentin.
9. History of suicide attempt.
10. No active suicidal plan/intent or active suicidal thoughts in the last 6 months.
11. Current use or use within the previous three months prior to screening of
antidepressant, anxiolytic, or antipsychotic agents. Subjects using benzodiazepines
for anxiety will not be permitted.
12. Diagnosis of Bipolar Disorder, Schizophrenia, psychotic disorder (excluding
post-ictal psychosis), Major Depression requiring hospitalization in the past 2
years, or other psychological or behavioral condition which in the judgement of the
investigator should exclude the subject from the study.
13. A history of alcoholism, drug abuse, or drug addiction within the last 2 years.
14. Any contraindication to use of PGB.
15. Any clinical condition (e.g. severe renal impairment, chronic hepatic disease,
serious infection, and or bone marrow depression) which will impair participation in
the trial.
16. History of multiple drug allergies or severe drug allergy.
17. Subjects with vagal nerve stimulators (VNS). |
|
|
|
| Study is available at: |
|
Northeast Regional Epilepsy Group
Hackensack, NJ 07601
United States
Primary Contact:
Hasan M Husaini, MS
Email: hhusaini@epilepsygroup.com
Phone: 201-343-6676 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 23, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|